These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 27749923)
1. Differential Adverse Event Profiles Associated with BCG as a Preventive Tuberculosis Vaccine or Therapeutic Bladder Cancer Vaccine Identified by Comparative Ontology-Based VAERS and Literature Meta-Analysis. Xie J; Codd C; Mo K; He Y PLoS One; 2016; 11(10):e0164792. PubMed ID: 27749923 [TBL] [Abstract][Full Text] [Related]
2. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients. Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445 [TBL] [Abstract][Full Text] [Related]
3. Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports. Guo W; Deguise J; Tian Y; Huang PC; Goru R; Yang Q; Peng S; Zhang L; Zhao L; Xie J; He Y Front Pharmacol; 2022; 13():870599. PubMed ID: 35814246 [TBL] [Abstract][Full Text] [Related]
4. Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines. Sarntivijai S; Xiang Z; Shedden KA; Markel H; Omenn GS; Athey BD; He Y PLoS One; 2012; 7(11):e49941. PubMed ID: 23209624 [TBL] [Abstract][Full Text] [Related]
6. Use of Bacillus Calmette-Guerin in superficial bladder cancer: a review. Talug C; Brown ET; Zaslau S; Kandzari SJ W V Med J; 2009; 105(3):17-9. PubMed ID: 19456033 [No Abstract] [Full Text] [Related]
7. OAE-based data mining and modeling analysis of adverse events associated with three licensed HPV vaccines. Zi W; Yang Q; Su J; He Y; Xie J Heliyon; 2022 Nov; 8(11):e11515. PubMed ID: 36411908 [TBL] [Abstract][Full Text] [Related]
9. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer. Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496 [TBL] [Abstract][Full Text] [Related]
10. Bacillus Calmette-Guérin (BCG) vaccine safety surveillance in the Korea Adverse Event Reporting System using the tree-based scan statistic and conventional disproportionality-based algorithms. Kim JH; Lee H; Shin JY Vaccine; 2020 May; 38(21):3702-3710. PubMed ID: 32278521 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Alexandroff AB; Nicholson S; Patel PM; Jackson AM Immunotherapy; 2010 Jul; 2(4):551-60. PubMed ID: 20636008 [TBL] [Abstract][Full Text] [Related]
12. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955 [TBL] [Abstract][Full Text] [Related]
13. Current challenges and opportunities for bacillus Calmette-Guérin replacement vaccine candidates. Méndez-Samperio P Scand J Immunol; 2019 Oct; 90(4):e12772. PubMed ID: 31055842 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapeutically induced cutaneous tuberculosis after BCG injection in a patient with pelvic osteosarcoma. Zoccali G; Cota C; Marolda G; Ferraresi V; Giuliani M; Zoccali C Surg Infect (Larchmt); 2012 Dec; 13(6):406-8. PubMed ID: 23240721 [TBL] [Abstract][Full Text] [Related]